SYMPHONY EVOLUTION
Symphony Evolution, Inc., a biopharmaceutical company, develops therapeutics to treat cancer and diabetic nephropathy. It involves in the development of clinical programs, including XL647, a potent inhibitor of receptor tyrosine kinases (RTK); XL999 that inhibits RTKs implicated in the development and maintenance of tumor vasculature; and XL784, a small molecule compound for renal disease. The company was incorporated in 2005 and is based in Rockville, Maryland
SYMPHONY EVOLUTION
Industry:
Health Care Pharmaceutical
Founded:
2005-01-01
Address:
Rockville, Maryland, United States
Country:
United States
Status:
Active
Contact:
301-762-3148